Fig. 4

Identification and validation of SPOCK1 as an EPCR effector. a Microarray analysis of mammary tumors developed in mice injected with 1833 cells. Heat map showing most relevant genes downregulated in both shEPCR#1 and shEPCR#2 tumors compared to shControl tumors. b Validation by RT-qPCR of SPOCK1 downregulation in subcutaneous xenograft tumors (1833 cells). Data are mean ± SEM of three tumors. c Expression levels of SPOCK1 in breast tumors from patients with low and high EPCR levels, classified by median expression value of EPCR (GSE2034 database). d Relapse-free survival analysis in patients from luminal B, HER2+, and basal subsets (GSE2034 database), classified into “high SPOCK1” and “low SPOCK1” based on the median expression value of SPOCK1. Log-rank test was used. e Quantification of spheres grown in 3D matrigel cultures. Data are mean ± SD of 8 replicates from two independent experiments. f Quantification of the number of spheres grown in 3D matrigel cultures in MCF10A cells overexpressing EPCR or SPOCK1. Data are mean ± SD of 8 replicates from two independent experiments. Representative images at ×4 magnification. Scale bar 0.5 mm. *p < 0.05; **p < 0.01; ***p < 0.001